Siga Technologies Inc (SIGA) 2.92 $SIGA
SIGA Technologies Reports Financial Results for the First Quarter 2014
GlobeNewswire - Thu May 01, 3:12PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter ended March 31, 2014.
Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a
SIGA to Host Quarterly Business Update Call on May 1, 2014
GlobeNewswire - Tue Apr 29, 7:00AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Thursday, May 1, 2014.
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
SIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2013
GlobeNewswire - Mon Mar 10, 3:01PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter and year ended December 31, 2013.
SIGA to Host Quarterly Business Update Call on March 10, 2014
GlobeNewswire - Mon Mar 03, 4:20PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, March 10, 2014.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encephalitis - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8dt7p/encephalitis) has announced the addition of the "Encephalitis - Pipeline Review, H2 2013" report to their offering. 'Encephalitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Encephalitis. - A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sanofi-Aventis Takeda Pharmaceutical Company Limited CEL-SCI Corporation SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Palau Pharma S.A AlphaVax, Inc. EpiVax, Inc. Wittycell S.A.S. Vaxart, Inc. Hawaii Biotech, Inc. NasVax Ltd. Prosetta Corporation Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/l8...cephalitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Second Quarter 2013
GlobeNewswire - Mon Aug 05, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and six months ended June 30, 2013.
Stock to Watch: SIGA Technologies Up 11.1% (SIGA)
Comtex SmarTrend(R) - Fri Aug 02, 10:16AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 11.1% to $3.61 on 1.4x average daily volume. SIGA Technologies has traded 315,000 shares thus far today, vs. average volume of 233,000 shares per day. The stock has outperformed the Dow (11.1% to the Dow's -0.4%) and outperformed the S&P 500 (11.1% to the S&P's -0.3%) during today's trading.
SIGA Selects Lead Candidate for Dengue Antiviral Program
GlobeNewswire - Thu Aug 01, 4:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral program.
SIGA to Host Second Quarter Business Update Call on August 5, 2013
GlobeNewswire - Tue Jul 30, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 5, 2013.
Siga qualifies for $79M smallpox drug payment
AP - Tue Jul 16, 10:26AM CDT
NEW YORK (AP) — Shares of Siga Technologies Inc. climbed Tuesday after the company said it qualified for about $79 million in payments after delivering more doses of its smallpox drug to the government.
Traders Get Bullish on Shares of SIGA Technologies, Shares Up 8.0% (SIGA)
Comtex SmarTrend(R) - Tue Jul 16, 10:17AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 8.0% to $3.51 on 1.2x average daily volume. SIGA Technologies has traded 294,000 shares thus far today, vs. average volume of 255,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.2%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
SIGA Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr(TM)
GlobeNewswire - Tue Jul 16, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced it has passed another significant commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS). With a cumulative delivery of approximately 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has met a key requirement of its contract with the Government's Biomedical Advanced Research and Development Authority (BARDA) and has qualified for a payment of approximately $79 million for the courses delivered to date.
SIGA, TESS, BVSN, SMTX, ZOLT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jul 02, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SIGA Technologies Inc (NASDAQ:SIGA), TESSCO TECHNOLOGIES INCORPORATED (NASDAQ:TESS), BroadVision Inc (NASDAQ:BVSN), SMTC Corp (NASDAQ:SMTX), Zoltek Companies Inc (NASDAQ:ZOLT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola and Marburg Infections - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7wtzj/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2013" report to their offering. "Ebola and Marburg Infections - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.
SIGA Completes Second Delivery of Arestvyr(TM) Under BARDA Contract
GlobeNewswire - Wed May 29, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced the Government's acceptance of SIGA's second delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS) under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA).
Delaware high court: SIGA liable in contract row
By The Associated Press - AP - Sun May 26, 5:17PM CDT
The Delaware Supreme Court has upheld a lower court's finding that SIGA Technologies Inc. is liable for breaching contractual obligations to negotiate in good faith with rival biodefense company PharmAthene.
Delaware Supreme Court Reverses Equitable Payment Stream to PharmAthene and Remands Litigation to Trial Court for New Determination of Damages
GlobeNewswire - Sun May 26, 3:12PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) reported today that the Delaware Supreme Court reversed the award of an "equitable payment stream" by the Court of Chancery in its May 31, 2012 Final Order and Judgment in PharmAthene, Inc. v. SIGA Technologies, Inc. and also remanded the case to the Court of Chancery for further proceedings to determine appropriate damages.
SIGA Technologies Reports Financial Results for the First Quarter 2014
GlobeNewswire - Thu May 01, 3:12PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter ended March 31, 2014.
Global Influenza A Infections Therapeutics Pipeline Review 2014 - Analysis of 23 Companies & 41 Drug profiles
M2 - Tue Apr 29, 8:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wjnvgk/influenza_a) has announced the addition of the "Influenza A Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Influenza A Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Influenza A Infections - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Vertex Pharmaceuticals Incorporated - Crucell N.V. - Hemispherx Biopharma, Inc. - Amarillo Biosciences, Inc. - SIGA Technologies, Inc. - Vironova AB - CureVac GmbH - PT Bio Farma - Viroblock S.A. - Innate Therapeutics Limited - Chimerix, Inc. - Theraclone Sciences, Inc. - Immune Targeting Systems (ITS) Ltd. - Sinovac Biotech Ltd. - Microbiotix, Inc. - Alios BioPharma, Inc. - ImmuneRegen BioSciences, Inc. - Vivaldi Biosciences Inc. - Humabs BioMed SA Drug Profiles - diridavumab - interferon alfa - FP-01 - CR-8020 - TCN-032 - midodrine hydrochloride - VX-787 - Avian Flu Vaccine - RG-7745 - Influenza A H7N7 vaccine - VIS-410 - Orvax - GSK-3206641-A - GSK-3206640A - H7N9 Vaccine - Homspera - rintatolimod - interferon alfa-n3 (human leukocyte derived) - Drug For Influenza A Infections - MIS-416 - Flufirvitide-3 - Nucleozin - Small Molecule For Influenza A - ET-001 - CR-8043 - FI-6 - Pam2Cys Vaccine For more information visit http://www.researchandmarkets.com/research/wj...nfluenza_a
SIGA to Host Quarterly Business Update Call on May 1, 2014
GlobeNewswire - Tue Apr 29, 7:00AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Thursday, May 1, 2014.
Global Dengue Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/m3qq9r/dengue_pipeline) has announced the addition of the "Global Dengue Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - GenVec, Inc. - Merck & Co., Inc. - Takeda Pharmaceutical Company Limited - FIT Biotech Oyj - Biological E. Limited - Biotron Limited - Sarepta Therapeutics, Inc. - Medivir AB - NanoViricides, Inc. - SIGA Technologies, Inc. - Panacea Biotec Limited - Bharat Biotech International Limited - Protein Potential, LLC - TechnoVax, Inc. - MacroGenics, Inc. - PTC Therapeutics, Inc. - Chimerix, Inc. - Immunotope, Inc. - Immunovaccine, Inc. - VaxInnate Corporation - Janssen Pharmaceuticals, Inc. - Cocrystal Discovery, Inc. - PaxVax - AltraVax Inc. - Oneness Biotech Co., Ltd. - Arbovax, Inc. - Sanofi Pasteur SA - Themis Bioscience GmbH - Agilvax, Inc. - Humabs BioMed SA - Codagenix, Inc. Drug Profiles - Dengue Vaccine - DENVax - TetraVax-DV Vaccine-Admixture TV003 - Attenuated Tetravalent Lyophilized Dengue Vaccine - celgosivir hydrochloride - TetraVax-DV Vaccine-Admixture 1 - TetraVax-DV Vaccine-Admixture 2 - TetraVax-DV Vaccine-Admixture TV005 - V-180 - Dengue Vaccine - DENV-1 PIV - ST-148 - DengueCide - TVX-005 - Dengue Vaccine - AVI-6006 - Dengue Vaccine - DV2G460P - squalamine lactate - ST-610 - Dengue Fever Vaccine - Dengue Tetravalent Vaccine - Vaccine For Dengue - Dengue Vaccine - CLEC5A mAb - Dengue Virus Vaccines - Dengue Virus Vacine - Dengue Vaccine - GREDEN/V1-4 - Subunit Vaccine For Dengue - Dengue Vaccine - DEN-2-JE Virus Chimeric Plasmid Vaccine - Chimeric Live-Attenuated Dengue Vaccine - DENV-1/2 prM E Chimeric Vaccine - Vaccine For Dengue - Small Molecules to Inhibit Furin for Dengue - DV-2-DeltaGVII - DV-2-DeltaLIG - Mult. mAbs/DARTs - Small Molecule for Dengue - Vaccine For Dengue Fever - Small Molecule for Viral Infections - Small Molecule to Inhibit NS3 Protease for Dengue - Viral PMO-X - Small Molecule For Dengue - LCTA-949 - DiTU - BG-323 - Small Moleucles to Activate AMPK for Dengue - Small Molecules to Inhhibit Serine Protease for Viral Infections - Subunit Vaccine for Dengue Fever For more information visit http://www.researchandmarkets.com/research/m3...e_pipeline
SIGA Technologies Reports Financial Results for the Fourth Quarter and Year Ended 2013
GlobeNewswire - Mon Mar 10, 3:01PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development and commercialization of solutions for serious unmet medical needs and biothreats, today reported its financial results for the quarter and year ended December 31, 2013.
SIGA to Host Quarterly Business Update Call on March 10, 2014
GlobeNewswire - Mon Mar 03, 4:20PM CST
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, March 10, 2014.
Ebola and Marburg Infections - Pipeline Review, H2 2013 Report
M2 - Tue Feb 04, 2:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/bv7mx8/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H2 2013" report to their offering. 'Ebola and Marburg Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Ebola and Marburg Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Inovio Pharmaceuticals, Inc. Bavarian Nordic A/S Crucell N.V. NanoViricides, Inc. SIGA Technologies, Inc. Functional Genetics, Inc. Okairos AG AlphaVax, Inc. Immunovaccine, Inc. Mapp Biopharmaceutical, Inc. For more information visit http://www.researchandmarkets.com/research/bv...nd_marburg About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Encephalitis - Pipeline Review, H2 2013
M2 - Thu Sep 12, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l8dt7p/encephalitis) has announced the addition of the "Encephalitis - Pipeline Review, H2 2013" report to their offering. 'Encephalitis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Encephalitis, complete with latest updates, and special features on late-stage and discontinued projects. Scope - A snapshot of the global therapeutic scenario for Encephalitis. - A review of the Encephalitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Encephalitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Sanofi-Aventis Takeda Pharmaceutical Company Limited CEL-SCI Corporation SIGA Technologies, Inc. Panacea Biotec Limited Functional Genetics, Inc. Palau Pharma S.A AlphaVax, Inc. EpiVax, Inc. Wittycell S.A.S. Vaxart, Inc. Hawaii Biotech, Inc. NasVax Ltd. Prosetta Corporation Vaxine Pty Ltd For more information visit http://www.researchandmarkets.com/research/l8...cephalitis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
SIGA Technologies Reports Financial Results for the Second Quarter 2013
GlobeNewswire - Mon Aug 05, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today reported its financial results for the three and six months ended June 30, 2013.
Stock to Watch: SIGA Technologies Up 11.1% (SIGA)
Comtex SmarTrend(R) - Fri Aug 02, 10:16AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 11.1% to $3.61 on 1.4x average daily volume. SIGA Technologies has traded 315,000 shares thus far today, vs. average volume of 233,000 shares per day. The stock has outperformed the Dow (11.1% to the Dow's -0.4%) and outperformed the S&P 500 (11.1% to the S&P's -0.3%) during today's trading.
SIGA Selects Lead Candidate for Dengue Antiviral Program
GlobeNewswire - Thu Aug 01, 4:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral program.
SIGA to Host Second Quarter Business Update Call on August 5, 2013
GlobeNewswire - Tue Jul 30, 3:00PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) announced today that management will host a conference call and simultaneous webcast to provide a quarterly business update at 4:30 P.M. ET on Monday, August 5, 2013.
Siga qualifies for $79M smallpox drug payment
AP - Tue Jul 16, 10:26AM CDT
NEW YORK (AP) — Shares of Siga Technologies Inc. climbed Tuesday after the company said it qualified for about $79 million in payments after delivering more doses of its smallpox drug to the government.
Traders Get Bullish on Shares of SIGA Technologies, Shares Up 8.0% (SIGA)
Comtex SmarTrend(R) - Tue Jul 16, 10:17AM CDT
SIGA Technologies (NASDAQ:SIGA) is one of today's best performing low-priced stocks, up 8.0% to $3.51 on 1.2x average daily volume. SIGA Technologies has traded 294,000 shares thus far today, vs. average volume of 255,000 shares per day. The stock has outperformed the Dow (8.0% to the Dow's -0.2%) and outperformed the S&P 500 (8.0% to the S&P's -0.3%) during today's trading.
SIGA Meets Drug Delivery Condition Under BARDA Contract and Qualifies for First Payment for Delivering Arestvyr(TM)
GlobeNewswire - Tue Jul 16, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced it has passed another significant commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS). With a cumulative delivery of approximately 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has met a key requirement of its contract with the Government's Biomedical Advanced Research and Development Authority (BARDA) and has qualified for a payment of approximately $79 million for the courses delivered to date.
SIGA, TESS, BVSN, SMTX, ZOLT Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Tue Jul 02, 6:02AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SIGA Technologies Inc (NASDAQ:SIGA), TESSCO TECHNOLOGIES INCORPORATED (NASDAQ:TESS), BroadVision Inc (NASDAQ:BVSN), SMTC Corp (NASDAQ:SMTX), Zoltek Companies Inc (NASDAQ:ZOLT) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Ebola and Marburg Infections - Pipeline Review, H1 2013
M2 - Mon Jun 17, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h7wtzj/ebola_and_marburg) has announced the addition of the "Ebola and Marburg Infections - Pipeline Review, H1 2013" report to their offering. "Ebola and Marburg Infections - Pipeline Review, H1 2013", provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Ebola and Marburg Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ebola and Marburg Infections. Scope - A snapshot of the global therapeutic scenario for Ebola and Marburg Infections. - A review of the Ebola and Marburg Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.
SIGA Completes Second Delivery of Arestvyr(TM) Under BARDA Contract
GlobeNewswire - Wed May 29, 7:30AM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) today announced the Government's acceptance of SIGA's second delivery of its proprietary smallpox antiviral drug, Arestvyr(TM), to the United States Government's Strategic National Stockpile (SNS) under SIGA's contract with the Biomedical Advanced Research and Development Authority (BARDA).
Delaware high court: SIGA liable in contract row
By The Associated Press - AP - Sun May 26, 5:17PM CDT
The Delaware Supreme Court has upheld a lower court's finding that SIGA Technologies Inc. is liable for breaching contractual obligations to negotiate in good faith with rival biodefense company PharmAthene.
Delaware Supreme Court Reverses Equitable Payment Stream to PharmAthene and Remands Litigation to Trial Court for New Determination of Damages
GlobeNewswire - Sun May 26, 3:12PM CDT
SIGA Technologies, Inc. (Nasdaq:SIGA) reported today that the Delaware Supreme Court reversed the award of an "equitable payment stream" by the Court of Chancery in its May 31, 2012 Final Order and Judgment in PharmAthene, Inc. v. SIGA Technologies, Inc. and also remanded the case to the Court of Chancery for further proceedings to determine appropriate damages.
